Elisabeth Leiderman, MD

Lis Leiderman, MD, MBA, is Chief Financial Officer and Chief Business Officer at Atsena Therapeutics, a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness. Dr. Leiderman serves as a member of the board of directors and is Audit Chair of bluebird bio.

Dr. Leiderman has more than 15 years of expertise in business development, strategy, and finance in the life sciences industry. Before joining Atsena, she was Chief Financial Officer and Head of Corporate Development at Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders. She served as Chief Business Officer at Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases and Senior Vice President, Head of Corporate Development at Fortress Biotech, where she was responsible for key business growth initiatives, including business development, strategy, financial analysis and capital raising. Dr. Leiderman spent 10 years as a healthcare investment banker advising global corporate clients and their boards. Her significant transaction experience includes mergers and acquisitions, other strategic transactions, initial public offerings, and other equity and debt financings in the healthcare sector. She began her career in medical affairs at AstraZeneca in their neuroscience division. Dr. Leiderman earned an MD from the American Medical Program Tel Aviv University, an MBA from The Wharton School at the University of Pennsylvania and a BA from The University of Pennsylvania.

Dr. Leiderman lives in NYC with her family.